A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Peer Review reports

Original Submission
6 Apr 2020	Submitted	Original manuscript
26 May 2020	Reviewed	Reviewer Report - Kristen Andreatta
30 May 2020	Reviewed	Reviewer Report
29 Jun 2020	Author responded	Author comments - Collins Iwuji
Resubmission - Version 2
29 Jun 2020	Submitted	Manuscript version 2
5 Jul 2020	Author responded	Author comments - Collins Iwuji
Resubmission - Version 3
5 Jul 2020	Submitted	Manuscript version 3
Publishing
7 Jul 2020	Editorially accepted
20 Jul 2020	Article published	10.1186/s12879-020-05240-y

Back to article page